Mechanism-linked potency assays drive gene therapy success
VectorBuilder’s Alan Griffith explains the value of MoA-reflective potency assays for gene therapy development and the benefits of working with assay specialists like Svar Life Science
Clinical Diagnostics
The global #CLINICAL24 2025 conversation has begun! Tell us your daily challenges and let's explore the solutions together
Explore topics
Drug Discovery
Transform your lab with advanced digitalized tools to accelerate drug discovery and development seamlessly
Explore feature
Life Sciences
Explore the latest advances in tumor biology and see how science is turning discovery into action against cancer
Explore feature
